Mineralys Therapeutics, Inc. Common Stock

$14.54
(as of Jul 3, 1:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Mineralys Therapeutics, Inc. Common Stock

Stock Price
$14.54
Ticker Symbol
MLYS
Exchange
NASDAQ

Industry Information for Mineralys Therapeutics, Inc. Common Stock

Sector
Healthcare
Industry
Biotechnology

Company Description for Mineralys Therapeutics, Inc. Common Stock

Country
USA
Full Time Employees
51

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Fundamentals for Mineralys Therapeutics, Inc. Common Stock

Market Capitalization
$892,901,568
EBITDA
$-201,438,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-3.75
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
65,175,300
Percent Owned by Insiders
1.46%
Percent Owned by Institutions
98.73%
52-Week High
52-Week Low

Technical Indicators for Mineralys Therapeutics, Inc. Common Stock

50-Day Moving Average
200-Day Moving Average
RSI
50.79
0.76

Analyst Ratings for Mineralys Therapeutics, Inc. Common Stock

Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0

News About Mineralys Therapeutics, Inc. Common Stock

Jul 1, 2025, 2:42 AM EST
Mineralys Therapeutics, Inc. See more.
Jun 30, 2025, 11:17 AM EST
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – See more.
Jun 17, 2025, 7:05 AM EST
RADNOR, Pa. - Mineralys Therapeutics, Inc. See more.
May 24, 2025, 4:30 AM EST
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – See more.